Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of iptacopan in generalized myasthenia gravis with open-label extension
CTR20243185Phase 3Active
- Sponsor
- Novartis
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Iptacopan in myasthenia gravis (MG), sponsored by Novartis. Started Dec 2024; status: active.
02
Drugs
Iptacopan
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on CTR20243185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243185.